Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13311-017-0519-x http://scihub22266oqcxt.onion/10.1007/s13311-017-0519-x C5398991!5398991!28281173     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Neurotherapeutics 2017 ; 14 (2): 284-97 Nephropedia Template TP {{tp|p=28281173|t=2017. Glioma Subclassifications and Their Clinical Significance |pdf=|usr=}}{{28281173}} gab.com Text Glioma Subclassifications and Their Clinical Significance JO: Neurotherapeutics http://www.kidney.de/pget.php?&tw=1&pmid=28281173 #FOAvip The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, lomustine, vincristine]), and tumor-treating fields, are based on nonspecific targeting of proliferating cells. Recent advances in the molecular understanding of gliomas suggest some potential reasons for the failure of more targeted therapies in gliomas. Specifically, the histologic-based glioma classification is composed of multiple different molecular subtypes with distinct biology, natural history, and prognosis. As a result of these insights, the diagnosis and classification of gliomas have recently been updated by the World Health Organization. However, these changes and other novel observations regarding glioma biomarkers and subtypes highlight several clinical challenges. First, the field is faced with the difficulty of reinterpreting the results of prior studies and retrospective data using the new classifications to clarify prognostic assessments and treatment recommendations for patients. Second, the new classifications and insights require rethinking the design and stratification of future clinical trials. Last, these observations provide the essential framework for the development and testing of new specific targeted therapies for particular glioma subtypes. This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field.Electronic supplementary material: The online version of this article (doi:10.1007/s13311-017-0519-x) contains supplementary material, which is available to authorized users. Twit Text FOAVip Glioma Subclassifications and Their Clinical Significance ????Neurotherapeutics http://www.kidney.de/pget.php?&tw=1&pmid=28281173 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28281173 #FOAvip English Wikipedia <ref>{{Cite pmid|28281173}}</ref> Glioma Subclassifications and Their Clinical Significance #MMPMID28281173 Chen R; Smith-Cohn M; Cohen AL; Colman H Neurotherapeutics 2017[Apr]; 14 (2): 284-97 PMID28281173show ga The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, lomustine, vincristine]), and tumor-treating fields, are based on nonspecific targeting of proliferating cells. Recent advances in the molecular understanding of gliomas suggest some potential reasons for the failure of more targeted therapies in gliomas. Specifically, the histologic-based glioma classification is composed of multiple different molecular subtypes with distinct biology, natural history, and prognosis. As a result of these insights, the diagnosis and classification of gliomas have recently been updated by the World Health Organization. However, these changes and other novel observations regarding glioma biomarkers and subtypes highlight several clinical challenges. First, the field is faced with the difficulty of reinterpreting the results of prior studies and retrospective data using the new classifications to clarify prognostic assessments and treatment recommendations for patients. Second, the new classifications and insights require rethinking the design and stratification of future clinical trials. Last, these observations provide the essential framework for the development and testing of new specific targeted therapies for particular glioma subtypes. This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field.Electronic supplementary material: The online version of this article (doi:10.1007/s13311-017-0519-x) contains supplementary material, which is available to authorized users. äGlioma Subclassifications and Their Clinical Significance (epmc).pdf DeepDyve Pubget Overpricing